[go: up one dir, main page]

DK0587738T3 - Destineret levering af gener, som koder for sekretionsproteiner - Google Patents

Destineret levering af gener, som koder for sekretionsproteiner

Info

Publication number
DK0587738T3
DK0587738T3 DK92912929T DK92912929T DK0587738T3 DK 0587738 T3 DK0587738 T3 DK 0587738T3 DK 92912929 T DK92912929 T DK 92912929T DK 92912929 T DK92912929 T DK 92912929T DK 0587738 T3 DK0587738 T3 DK 0587738T3
Authority
DK
Denmark
Prior art keywords
gene
cell
binding agent
specific
secretory protein
Prior art date
Application number
DK92912929T
Other languages
English (en)
Inventor
George Y Wu
James M Wilson
Catherine H Wu
Original Assignee
Univ Connecticut
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut, Univ Michigan filed Critical Univ Connecticut
Application granted granted Critical
Publication of DK0587738T3 publication Critical patent/DK0587738T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Processing Or Creating Images (AREA)
  • Digital Computer Display Output (AREA)
  • Document Processing Apparatus (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Medicinal Preparation (AREA)
DK92912929T 1991-06-05 1992-06-05 Destineret levering af gener, som koder for sekretionsproteiner DK0587738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71055891A 1991-06-05 1991-06-05
PCT/US1992/004565 WO1992022635A1 (en) 1991-06-05 1992-06-05 Targeted delivery of genes encoding secretory proteins

Publications (1)

Publication Number Publication Date
DK0587738T3 true DK0587738T3 (da) 2000-12-18

Family

ID=24854525

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92912929T DK0587738T3 (da) 1991-06-05 1992-06-05 Destineret levering af gener, som koder for sekretionsproteiner

Country Status (10)

Country Link
EP (1) EP0587738B1 (da)
JP (1) JPH06510278A (da)
AT (1) ATE195656T1 (da)
AU (2) AU2160992A (da)
CA (1) CA2103371C (da)
DE (1) DE69231385T2 (da)
DK (1) DK0587738T3 (da)
ES (1) ES2149774T3 (da)
GR (1) GR3034882T3 (da)
WO (1) WO1992022635A1 (da)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
DK0636028T3 (da) * 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
US5656609A (en) * 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
AU6624594A (en) * 1993-04-05 1994-10-24 Albert Einstein College Of Medicine Of Yeshiva University Targeted delivery of genes encoding cellular microsomal enzymes
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US6468981B1 (en) * 1994-07-29 2002-10-22 Emory University Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0904373A1 (en) * 1996-03-14 1999-03-31 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1998055611A1 (en) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
NZ528767A (en) 1998-03-30 2005-08-26 Northwest Biotherapeutics Inc Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
JP4227302B2 (ja) 1998-04-07 2009-02-18 コリクサ コーポレイション Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ抗原の融合タンパク質およびその使用
GB9817084D0 (en) * 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
PT1129064E (pt) 1998-11-12 2008-01-31 Invitrogen Corp Reagentes de transfecção
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6759393B1 (en) 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
AU5269800A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in allergy cells
EP1230349B1 (en) 1999-11-18 2007-06-13 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
DK1250453T3 (da) 1999-12-10 2008-08-11 Invitrogen Corp Anvendelse af multiple rekombinations-sites med unik specificitet i rekombinationskloning
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EP1967206B1 (en) 2000-08-30 2012-10-10 Pfizer Products Inc. Anti-IgE vaccines
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
WO2002079447A2 (en) 2001-03-30 2002-10-10 Avigenics, Inc. Avian lysozyme promoter
EP1385864B1 (en) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 antibodies
FI116851B (fi) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
JP2005500835A (ja) 2001-06-29 2005-01-13 ノバルティス アクチエンゲゼルシャフト Ｐｅｒｖスクリーニング法およびその使用
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
EP2360476B1 (en) 2002-02-13 2017-10-25 BioMedica Diagnostics Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
DK1534335T4 (da) 2002-08-14 2015-10-05 Macrogenics Inc Fcgammariib-specifikke antistoffer og fremgangsmåder til anvendelse deraf
EP2218779A1 (en) 2002-12-16 2010-08-18 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2004071462A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
JP4895291B2 (ja) 2003-06-13 2012-03-14 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー Ｒｎａインターフェラーゼおよびその使用方法
JP2008500005A (ja) 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
EP1668111A4 (en) 2003-08-08 2008-07-02 Genenews Inc OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
WO2005032572A2 (en) 2003-10-03 2005-04-14 Vib Vzw Means and methods for the recruitment and identification of stem cells
US20050227251A1 (en) 2003-10-23 2005-10-13 Robert Darnell Method of purifying RNA binding protein-RNA complexes
EP1692262B1 (en) 2003-10-27 2018-08-15 Merck Sharp & Dohme Corp. Method of designing sirnas for gene silencing
HUE064610T2 (hu) 2003-12-23 2024-04-28 Genentech Inc Új anti-IL 13 antitestek és alkalmazásaik
CN101426489A (zh) 2004-04-16 2009-05-06 曹义海 抑制血管生成的成分和方法
EP1747292B1 (en) 2004-05-07 2015-07-08 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
US9228008B2 (en) 2004-05-28 2016-01-05 Idexx Laboratories, Inc. Canine anti-CD20 antibodies
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
US20090325150A1 (en) 2004-07-30 2009-12-31 Mount Sinai School Of Medicine Of New York University Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006055635A2 (en) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions and methods for altering wnt autocrine signaling
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
JP2008525479A (ja) 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
ES2409686T3 (es) 2005-01-25 2013-06-27 Prolexys Pharmaceuticals, Inc. Derivados de quinoxalina como agentes antitumorales
EP2520669A3 (en) 2005-02-07 2013-02-27 GeneNews Inc. Mild osteoathritis biomarkers and uses thereof
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
WO2006125141A2 (en) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
WO2007005898A2 (en) 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
JP5237817B2 (ja) 2005-10-21 2013-07-17 ジーンニュース インコーポレーティッド バイオマーカー産物レベルを疾患に相関させるための方法および装置
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
JP5367563B2 (ja) 2006-03-30 2013-12-11 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
KR101314362B1 (ko) 2006-08-28 2013-10-10 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
WO2008063769A2 (en) 2006-10-10 2008-05-29 The Henry M.Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
CA2669095A1 (en) 2006-11-15 2008-05-29 Functional Genetics, Inc. Anti-tsg101 antibodies and their uses for treatment of viral infections
MX2009006500A (es) 2006-12-18 2009-06-26 Genentech Inc Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3.
WO2008092041A2 (en) 2007-01-24 2008-07-31 Carnegie Mellon University Optical biosensors
US8211858B2 (en) 2007-04-27 2012-07-03 The University Of Toledo Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
PL2158221T3 (pl) 2007-06-21 2019-02-28 Macrogenics, Inc. Kowalencyjne diaciała i ich zastosowania
US20110206673A1 (en) 2007-06-27 2011-08-25 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
NO2195023T3 (da) 2007-08-29 2018-08-04
CN107236044B (zh) 2008-04-02 2021-07-02 宏观基因有限公司 HER2/neu-特异性抗体和其使用方法
CN102046655B (zh) 2008-04-02 2016-09-14 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
EP2282770B1 (en) 2008-06-04 2018-03-07 MacroGenics, Inc. Antibodies with altered binding to fcrn and methods of using same
DK2324060T3 (da) 2008-09-07 2015-10-26 Glyconex Inc Anti-forlænget type i-glycosphingolipid-antistof, derivater deraf og anvendelse
AU2009335798B2 (en) 2008-12-19 2014-11-27 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2752854A1 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
WO2010124365A1 (en) 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
EP2488186B1 (en) 2009-10-16 2017-05-24 National University of Singapore Anti-neoplastic uses of artemin antagonists
JP5908406B2 (ja) 2009-11-02 2016-04-26 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
WO2011088435A1 (en) 2010-01-15 2011-07-21 Cornell University Methods for reducing protein levels in a cell
WO2011150079A1 (en) 2010-05-25 2011-12-01 Carnegie Mellon University Targeted probes of cellular physiology
MX343298B (es) 2010-07-09 2016-11-01 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
EP3026432A3 (en) 2010-12-27 2016-07-27 Brown University Method for predicting patient's response to biglycan treatment
MX354618B (es) 2011-02-10 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Sistema de nanopartículas nts-poliplex para terapia génica de cáncer.
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
WO2013040341A2 (en) 2011-09-16 2013-03-21 Ottawa Hospital Research Institute Wnt7a compositions and methods of using the same
SG11201400668SA (en) 2011-09-16 2014-04-28 Fate Therapeutics Inc Wnt compositions and therapeutic uses of such compositions
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
LT2814844T (lt) 2012-02-15 2017-10-25 Novo Nordisk A/S Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
EP3142700B1 (en) 2014-05-16 2021-03-03 Medimmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016009086A1 (en) 2014-07-17 2016-01-21 Novo Nordisk A/S Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
CN107429075B (zh) 2014-11-17 2022-11-01 卡内基梅隆大学 可激活的双组份光敏剂
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
WO2016191418A1 (en) 2015-05-26 2016-12-01 Salk Institute For Biological Studies Motor neuron-specific expression vectors
WO2017182981A1 (en) 2016-04-20 2017-10-26 Washington University Ppar agonist or lxr agonist for use in the treatment of systemic lupus erythematosus by modulation of lap activity
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
KR20230135586A (ko) 2021-01-24 2023-09-25 마이클 데이비드 포레스트 Atp 합성효소 억제제 - 미용 및 치료 용도
CA3226402A1 (en) 2021-07-19 2023-01-26 Dounia ABBADI Adeno-associated viral vector compositions and methods of promoting muscle regeneration
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
CN119948051A (zh) 2022-07-15 2025-05-06 詹森生物科技公司 用于改善抗原结合可变区的生物工程化配对的材料和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules

Also Published As

Publication number Publication date
ES2149774T3 (es) 2000-11-16
DE69231385T2 (de) 2001-04-12
ATE195656T1 (de) 2000-09-15
GR3034882T3 (en) 2001-02-28
JPH06510278A (ja) 1994-11-17
EP0587738A1 (en) 1994-03-23
DE69231385D1 (de) 2000-09-28
CA2103371A1 (en) 1992-12-06
WO1992022635A1 (en) 1992-12-23
CA2103371C (en) 2003-09-16
AU5580896A (en) 1996-08-29
AU2160992A (en) 1993-01-12
EP0587738B1 (en) 2000-08-23

Similar Documents

Publication Publication Date Title
DK0587738T3 (da) Destineret levering af gener, som koder for sekretionsproteiner
DK0584279T3 (da) Målrettet aflevering af gener, som koder for immunogene proteiner
He et al. Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer
Kircheis et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery
Suryaprakash et al. Engineered mesenchymal stem cell/nanomedicine spheroid as an active drug delivery platform for combinational glioblastoma therapy
Hou et al. Protein PEPylation: a new paradigm of protein–polymer conjugation
Wang et al. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide
Dosta et al. Delivery of anti‐microRNA‐712 to inflamed endothelial cells using poly (β‐amino ester) nanoparticles conjugated with VCAM‐1 targeting peptide
Qian et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway
Xu et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes
Hu et al. Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy
Taranejoo et al. A review of the developments of characteristics of PEI derivatives for gene delivery applications
Hu et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection
Ryan et al. Advances in PEGylation of important biotech molecules: delivery aspects
Uz et al. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer
Yu et al. Epidermal growth factor–PEG functionalized PAMAM-pentaethylenehexamine dendron for targeted gene delivery produced by click chemistry
He et al. Combinatorial optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted pDNA and siRNA delivery
Fernandez et al. Engineered nanoscaled polyplex gene delivery systems
Paliwal et al. Liposomal nanomedicine for breast cancer therapy
Wang et al. Double click-functionalized siRNA polyplexes for gene silencing in epidermal growth factor receptor-positive tumor cells
Yang et al. HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells
Urbiola et al. Efficient targeted gene delivery by a novel PAMAM/DNA dendriplex coated with hyaluronic acid
Wang et al. Enzyme-activatable interferon–poly (α-amino acid) conjugates for tumor microenvironment potentiation
Azimifar et al. Evaluation of the efficiency of modified PAMAM dendrimer with low molecular weight protamine peptide to deliver IL‐12 plasmid into stem cells as cancer therapy vehicles
Kim et al. Antibody-assisted delivery of a peptide–drug conjugate for targeted cancer therapy